Your Strongest Ally to Conquer Cancer

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911




Latest Cancer News

Neratinib Improves Cancer-Free Survival in Early Breast Cancer (07-27-2016)

The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is... Continue Reading

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer (07-26-2016)

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer... Continue Reading

3-Year Survival Improved with Taflinar®/Mekinist® Combination in Advanced Melanoma (07-21-2016)

Patients with advanced melanoma who were treated with the combination consisting of Taflinar (dabrafenib) plus Mekinist (trametinib) had a significantly improved survival rate at 3 years compared to those treated with Taflinar only. These results were... Continue Reading

Loxo Oncology Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for LOXO-101 (07-19-2016)

Loxo Oncology, Inc. (LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy... Continue Reading

FDA Places Hold on a Trial Evaluating Genetically Engineered Immune Cells for Cancer Treatment (07-18-2016)

The United States Food and Drug Administration (FDA) has placed a hold on a clinical trial, referred to as the ROCKET trial, due to side effects of the treatment that may be associated with 3 patient deaths. Chimeric antigen receptor (CAR) technology... Continue Reading

Niraparib Improves Progression-Free Survival in Ovarian Cancer (07-13-2016)

The PARP inhibitor niraparib improves the time to cancer progression among patients with recurrent ovarian cancer when used as maintenance therapy during platinum-based chemotherapy. Each year in the United States, approximately 22,000 women are diagnosed... Continue Reading

Syndros™ Approved for Treating Chemotherapy-Induced Nausea and Vomiting (07-12-2016)

The orally administered liquid formulation, Syndros (dronabinol), has been approved by the United States Food and Drug Administration (FDA) for the treatment of chemotherapy-induced nausea and vomiting. Syndros is an oral formulation comparable to the... Continue Reading

Imbruvica® Effective in Newly Diagnosed and Recurrent Chronic Lymphocytic Leukemia (07-11-2016)

Imbruvica (ibrutinib) produces long-lasting anti-cancer responses among patients with newly diagnosed chronic lymphocytic leukemia (CLL), as well as those who have received prior therapies. These results were recently presented at the 2016 annual meeting... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (07-7-2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently published in the journal Blood. Multiple myeloma... Continue Reading

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (06-30-2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with advanced triple-negative breast cancer (TNBC). These... Continue Reading

Novel Antibody Improves Survival in Advanced Stomach Cancer (06-28-2016)

The novel agent, IMAB362, which stimulates the immune system to attack a certain protein expressed by many stomach cancer cells, has demonstrated a significant improvement in survival compared to standard therapy among patients with this disease. These... Continue Reading

Stent Placement Reduces Need for Stoma in Some Colorectal Cancers (06-27-2016)

The placement of a stent as initial emergency treatment for colon obstruction reduces the need for a stoma without adversely affecting outcomes for patients with potentially curable colorectal cancer. These results were recently presented at the 2016... Continue Reading

Next Page »